Whether youre focused on anti-aging, post-procedure recovery, or scar reduction, our approach supports long-term results with clinical backing
Insurance coverage remains limited for AOD 9604 as it is not FDA-approved for weight loss, though some flexible spending accounts accept the expense when prescribed for specific medical conditions
Market growth is supported by several factors including an aging global population, increasing prevalence of chronic diseases, and growing acceptance of biological therapies
In vitro evidence shows reduced ROS accumulation, improved mitochondrial membrane potential, and enhanced glutathione levels following GHK-Cu exposure
Additional trials in the TRIUMPH program may address retatrutide effects on cardiovascular outcomes, sleep apnea resolution, and kidney function, though these have not yet been formally announced